Alnylam Pharmaceuticals and Dicerna Pharmaceuticals have formed a development and commercialization collaboration on investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin (A1AT) deficiency-associated liver disease (alpha-1 liver disease).
Gilead Sciences and Second Genome, a leader in microbiome science, announced that the companies have entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up to five of Gilead’s pipeline compounds in inflammation, fibrosis and other diseases, and to identify potential new targets and drug candidates for the treatment of inflammatory bowel disease (IBD).
GlaxoSmithKline (GSK) has collaborated with Vir Biotechnology for the research and development of solutions for coronaviruses.
Shenogen has entered into an exclusive collaboration and licensing agreement with Shanghai BioArdis and BioArdis for the development and commercialization of BioArdis' novel FGFR4 (fibroblast growth factor receptor 4) kinase inhibitor, BIO-1262/SNG-203, either as monotherapy or combination therapy in Mainland China, Hong Kong, Macau and Taiwan.
Vir Biotechnology and Alnylam Pharmaceuticals, Inc. announced an expansion to their broad multi-target existing collaboration for the development and commercialization of RNAi therapeutics for infectious diseases, including SARS-CoV-2, the virus that causes the disease COVID-19.
Novartis has unveiled plans to commence a clinical trial of Jakavi (ruxolitinib) in severe COVID-19 patients and establish an international compassionate use programme.
Citius Pharmaceuticals has entered into an exclusive six-month option agreement with Novellus subsidiary to licence novel stem-cell therapy for acute respiratory distress syndrome (ARDS) associated with COVID-19, the disease caused due to the novel coronavirus SARS-CoV-2.
Tsinghua University has joined forces with 3rd People’s Hospital of Shenzhen and Brii Biosciences (Brii Bio) to develop neutralising antibodies against COVID-19 (novel coronavirus).
VBI Vaccines, a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced a collaboration with the National Research Council of Canada (NRC), Canada’s largest federal research and development organization, to develop a pan-coronavirus vaccine candidate, targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).
Eli Lilly has entered into a potential $880m research deal with Sitryx to discover and develop new immunometabolic medicines.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.